

North Central Cancer Treatment Group

N0572      A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent  
Glioblastoma

Status Change – July 17, 2006

**NOTICE OF STATUS CHANGE**

This study is temporarily suspended to patient accrual effective July 17, 2006. Following this date, patient entry will not be permitted until further notification is issued.

Patient accrual to dose level 0 has been met.

**Please retain this notice with the protocol.**